



April 25, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated April 25, 2025, titled **“Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA

Ahmedabad, India / Valence, France, April 25, 2025

Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited (“**Zydus**”) and Amplitude Surgical SA (“**Amplitude**”) confirm that Amplitude has conducted the mandatory information and consultation process with the works council of Amplitude SAS. Consequently, Zydus has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude¹ at a price of €6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on March 11, 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude (the “**Block Acquisition**”).

As indicated in the joint announcement of March 11, 2025, the completion of the Block Acquisition remains subject to the usual closing conditions, including authorization from the French Minister of Economy as part of the control of foreign investments in France, the re-investment by Amplitude CEO Olivier Jallabert into the company, as well as the absence of qualified material adverse events.

Subject to the fulfilment of the closing conditions, Zydus will acquire 85.6% of the share capital of Amplitude.

The closing of the Block Acquisition is now expected to be completed by Q3 2025. After such completion, Zydus’ mandatory simplified tender offer would be filed with the *Autorité des Marchés Financiers* (“**AMF**”) and would be followed by a squeeze out if the conditions are met. The opening of the subsequent tender offer would then remain subject to the AMF’s clearance decision.

In this respect and as announced on April 17, 2025, commitments to tender 4.7% of Amplitude’s share capital have been executed with other minority shareholders of Amplitude. As a consequence, and subject to the condition precedents hereabove, Zydus will be in a position to acquire more than 90 % of the capital and voting rights of Amplitude at the end of the tender offer, and therefore to implement a squeeze-out procedure.

Contact Information

Zydus Lifesciences Limited

Sujatha Rajesh
Media Relations
sujatha.rajesh@zyduslife.com
+91-9974051180

Arvind Bothra
Investor Relations
arvind.bothra@zyduslife.com
+91-7045656895

Brunswick
Media Relations
zydus@brunswickgroup.com
Hugues Boëton +33 6 79 99 27 15
Flora Marinho +33 6 07 46 34 35

Amplitude Surgical

Amplitude Surgical
Chief Financial Officer
Dimitri Borchtch
finances@amplitude-surgical.com
+33 4 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
+33 1 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 1 44 71 94 98

¹ Directly and indirectly through the acquisition of holding companies Auroralux, Amplitman 1 and Amplitman 2

PAI Partners

Dania Saidam

daniasaidam@paipartners.com

+44 20 7297 4678

About Zydus Lifesciences

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high-end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. As of June 30, 2024, Amplitude Surgical employed 428 people and generated sales of nearly €106.0 million.